Cargando…

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus

Alzheimer’s disease (AD) is characterized by memory loss and cognitive decline. Additionally, abnormal extracellular amyloid plaques accumulation and nerve damage caused by intracellular neurofibrillary tangles, and tau protein are characteristic of AD. Furthermore, AD is associated with oxidative s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sim, A Young, Barua, Sumit, Kim, Jong Youl, Lee, Yong-ho, Lee, Jong Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417940/ https://www.ncbi.nlm.nih.gov/pubmed/34489627 http://dx.doi.org/10.3389/fnins.2021.708547

Ejemplares similares

Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Correction: Comparison of SGLT2 inhibitors with DPP4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus
por: Lyu, Young Sang, et al.
Publicado: (2023)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
por: Gu, Namyi, et al.
Publicado: (2020)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

Adiponectin: The Potential Regulator and Therapeutic Target of Obesity and Alzheimer’s Disease
por: Kim, Jong Youl, et al.
Publicado: (2020)

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes
por: Cha, Seon-Ah, et al.
Publicado: (2017)

The role of NOX inhibitors in neurodegenerative diseases
por: Barua, Sumit, et al.
Publicado: (2019)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Efficacy of Body Weight Reduction on the SGLT2 Inhibitor in People with Type 2 Diabetes Mellitus
por: Cho, Hyun A, et al.
Publicado: (2017)

Maintenance of the Neuroprotective Function of the Amino Group Blocked Fluorescence-Agmatine
por: Barua, Sumit, et al.
Publicado: (2021)

Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study
por: Berton, Alessandro Maria, et al.
Publicado: (2023)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Renoprotective Effect of Thai Patients with Type 2 Diabetes Mellitus Treated with SGLT-2 Inhibitors versus DPP-4 Inhibitors: A Real-World Observational Study
por: Chanawong, Apichaya, et al.
Publicado: (2023)

Connecting Alzheimer’s Disease With Diabetes Mellitus Through Amyloidogenic Evolvability
por: Ho, Gilbert, et al.
Publicado: (2020)

Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society
por: Nakai, Michikazu, et al.
Publicado: (2022)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
por: Jung, Chang Hee, et al.
Publicado: (2014)

Role of agmatine in the application of neural progenitor cell in central nervous system diseases: therapeutic potentials and effects
por: Kosonen, Renée, et al.
Publicado: (2021)

THU287 Comparison Of Renal Protective Effects Between SGLT2 Inhibitors And DPP4 Inhibitors In Real-World Clinical Practice
por: Park, Hyeong-Kyu, et al.
Publicado: (2023)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Lee, Heeyoung, et al.
Publicado: (2021)

SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
por: Korbut, Anton I., et al.
Publicado: (2020)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
por: Bailey, Clifford J., et al.
Publicado: (2019)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

DPP-4 Inhibitors Improve Liver Dysfunction in Type 2 Diabetes Mellitus
por: Kanazawa, Ippei, et al.
Publicado: (2014)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
por: El Hage, Lea, et al.
Publicado: (2020)

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
por: Nomiyama, Takashi
Publicado: (2020)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study
por: Kim, Young-Gun, et al.
Publicado: (2016)

The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs
por: Giugliano, Dario, et al.
Publicado: (2022)

Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients With Type 2 Diabetes and Varying Baseline HbA(1c) Levels
por: D’Andrea, Elvira, et al.
Publicado: (2023)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus
por: Yu, Dong-Ni, et al.
Publicado: (2020)

Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction
por: Gonzalez, Jimmy, et al.
Publicado: (2023)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND DPP4I IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Kim, Dae H, et al.
Publicado: (2019)

Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
por: Kim, Kyuho, et al.
Publicado: (2021)

The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
por: Choe, Eun Yeong, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ronem1l69t78mf4622j91f72se